Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3297 - Optimizing Physician Surveys in Pharmacovigilance Using ecancer Online Community


10 Sep 2017


Poster display session


Supportive Care and Symptom Management


Jean-Jacques Body


Annals of Oncology (2017) 28 (suppl_5): v543-v567. 10.1093/annonc/mdx388


J. Body1, O. Nicolatou-Galitis2, J.M. Sprafka3, A. Stepto4, R.A. Gleave4, C. Hartley5, D. Niepel6, A. Liede7

Author affiliations

  • 1 Dept Of Medicine, CHU Brugmann ULB, 1020 - Brussels/BE
  • 2 School Of Dentistry, University of Athens, Athens/GR
  • 3 Center For Observational Research, AMGEN - USA, Thousand Oaks/US
  • 4 E-learning, ecancer, Bristol/GB
  • 5 E-learning, ecancer, BS65RL - Bristol/GB
  • 6 Clinical Development, AMGEN - Austria, 1040 - Vienna/AT
  • 7 Center For Observational Research, AMGEN - USA, 94080 - South San Francisco/US


Abstract 3297


Physician knowledge surveys have increasingly been requested of drug manufacturers in the post-authorization setting as part of risk minimization plans. Surveys in pharmacovigilance require considerable time and resource, and result in low response rates and questionable representativeness. After EMA consultation, an educational programme was initiated with ecancer to evaluate the potential of online communities in measuring knowledge of drug safety risks. Here, we describe the baseline survey used to measure basic knowledge of osteonecrosis of the jaw (ONJ) risks among prescribers of bone targeting agents (BTAs).


Clinical experts developed 8 multiple choice questions on BTAs and ONJ risk as described in the summary of product characteristics. BTAs included denosumab, zoledronate, or pamidronate. Invitations were sent out to ecancer and ECCO members. Eligible were physicians who treated ≥5 new/continuing adult patients with bone metastases from solid tumours in the last 3 months (mos), currently practicing as an oncology specialist in the European Union, Switzerland or Norway, and prescribed a BTA in the last 12 mos. Responses for eligible and ineligible were compared.


Among visits to the online survey, 87% completed the questions: 336 eligible/ineligible respondents from 52 countries, 292 from 26 European countries. Ineligibility was driven by the criterion of treating ≥5 patients in last 3 mos. Eligible respondents (n = 182) had higher level of correct responses than those who did not meet eligibility: mean 81% vs. 73% (p 


Online professional communities offer a pragmatic and efficient approach for recruitment of physicians for knowledge assessments. Basic knowledge of ONJ risks was high overall in this ecancer proof of concept. The strategy can achieve responses representative of today’s physicians who seek information online. These findings may be compared with knowledge among physicians who may not seek information online.

Clinical trial identification

Legal entity responsible for the study





J-J. Body: Consultant for Amgen Inc. O. Nicolatou-Galitis: Consultant for Amgen J.M. Sprafka, A. Liede: Amgen Inc. Employee, including stock ownership D. Niepel: Amgen GmbH employee, including stock ownership All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.